Biykem Bozkurt
Cardiovascular Disease · Houston, TXNPI 1457361107
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $406,680 of the $605,606 with a category attached, or 67.2%. 29 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 32.9% of the total. 2025 is the largest year on record at $206,621, 3.6 times the $58,129 reported in 2019. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $1668.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$199K
- Abbott$56K
- Merck$48K
- Boehringer Ingelheim$47K
- Sanofi-aventis U.S. LLC$35K
- Regeneron$27K
- plus $193K from 23 others
Across 5 payments — averaging $2408.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$5K
- Bayer$4K
- Amgen$3K
What the payments were for
- Consulting fees$406,68067%
- Speaking & faculty fees$75,73413%
- Travel & lodging$116,45919%
- Food & beverage$6,7321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 71 | $199,290 |
| Abbott | 42 | $56,375 |
| Merck | 45 | $47,710 |
| Boehringer Ingelheim | 41 | $46,937 |
| Sanofi-aventis U.S. LLC | 8 | $34,795 |
| Regeneron | 31 | $27,076 |
| E.r. Squibb & Sons, L.L.C. | 15 | $19,381 |
| Vifor (international) Ltd. | 8 | $18,746 |
| Livanova USA, Inc. | 11 | $18,000 |
| Medtronic | 3 | $15,856 |
| Roche Diagnostics International Ltd | 6 | $15,202 |
| Abiomed | 15 | $12,578 |
| Bayer | 12 | $12,342 |
| Eli Lilly | 9 | $9,522 |
| Vifor Pharma, Inc. | 9 | $9,419 |
| Daiichi Sankyo Inc. | 6 | $8,819 |
| Astrazeneca UK Limited | 1 | $8,400 |
| American Regent | 1 | $6,678 |
| ZOLL Respicardia, Inc. | 6 | $5,852 |
| Baxter Healthcare | 6 | $5,019 |
| Amgen | 5 | $4,920 |
| AstraZeneca | 2 | $4,028 |
| Scpharmaceuticals Inc. | 2 | $4,000 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Roche Diagnostics Corporation | 1 | $3,390 |
| Novo Nordisk AS | 2 | $3,140 |
| Johnson & Johnson | 1 | $1,654 |
| Astrazeneca AB | 1 | $1,611 |
| Impulse Dynamics (USA) Inc. | 2 | $1,327 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$48,371
- CARDIOMEMS$28,625
- NO PRODUCT DISCUSSED$24,977
- CardioMEMS HF System$20,750
- Veltassa$18,112
- INJECTAFER$15,453
- VNS - Vitaria$10,625
- Kerendia$10,097
- MULTAQ$9,695
- VNS Therapy$7,375
- MOUNJARO$5,812
- remede System$5,775
- Renal - PD$4,924
- Absorb GT1$4,600
- FUROSCIX$4,000
- Tryvio$3,540
- OPTIMIZER$2,654
- XARELTO$1,654
- VERQUVO$1,602
- WINREVAIR$1,588
How this compares
$605,606 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
- Dipan ShahHouston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.